Lung Cancer

The last topic covered by Dr. Neal was on exciting work on molecular targets for squamous NSCLC.

Here is Dr. Neal's summary from the ASCO 2012 Lung Cancer Highlights program of the SELECT Trial, which he led and presented, of adjuvant (post-operative) Tarceva (erlotinib) for patients with resected early stage EGFR mutation-positive NSCLC.

While the main story coming out of the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology focused on the relatively disappointing results of the PointBreak trial, one positive trial received quite a bit of attention.  Dr.

We've been producing a series of podcasts from our Lung Cancer Highlights from ASCO 2012 webinar, featuring Drs.

As part of our program on lung cancer highlights, Dr.

One of the more eagerly awaited clinical trials in lung cancer this year is the PointBreak study that tried to identify whether an Alimta (pemetrexed)-based first line and maintenance chemo strategy is significantly superior to a well-established standard first line and maintenance therapy regimen.  Specifically, this trial randomized 939 chemo-naive patients wi

Continuing with our post-ASCO highlights presentation, we now turn to Dr. Joel Neal, Assistant Professor at Stanford Cancer Center, who covered several targeted therapy options that are still working their way through investigational work.

Dr. Mark Socinski covered the TAILOR trial, an Italian study directly comparing second line Taxotere (docetaxel) to Tarceva (erlotinib) in advanced NSCLC patients without an EGFR mutation, in the ASCO Lung Cancer Highlights program.